Intellia Therapeutics Inc (38I)

Frankfurt
Currency in EUR
8.7340
+1.7580(+25.20%)
Closed·
38I Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
7.74408.8300
52 wk Range
5.300025.2300
Key Statistics
Edit
Bid/Ask
8.292 / 8.40
Prev. Close
6.976
Open
7.744
Day's Range
7.744-8.83
52 wk Range
5.3-25.23
Volume
5.83K
Average Volume (3m)
674
1-Year Change
-70.93%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
38I Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
14 analysts have revised their earnings upwards for the upcoming period

Intellia Therapeutics Inc News & Analysis

Show more

Intellia Therapeutics Inc Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Compare 38I to Peers and Sector

Metrics to compare
38I
Peers
Sector
Relationship
P/E Ratio
−1.8x−0.9x−0.5x
PEG Ratio
−0.870.020.00
Price/Book
1.2x1.4x2.6x
Price / LTM Sales
20.4x5.0x3.1x
Upside (Analyst Target)
-314.8%48.6%
Fair Value Upside
Unlock39.3%8.9%Unlock

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-1.10 / --
Revenue / Forecast
16.63M / --
EPS Revisions
Last 90 days

38I Income Statement

People Also Watch

70.04
TEM
-2.72%
15.550
QBTS
-2.84%
10.56
TXG
-4.09%
9.920
ACHR
-4.43%
11.485
RGTI
-5.55%

FAQ

What Is the Intellia Therapeutics Inc (38I) Stock Price Today?

The Intellia Therapeutics Inc stock price today is 8.73

What Stock Exchange Does Intellia Therapeutics Inc Trade On?

Intellia Therapeutics Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Intellia Therapeutics Inc?

The stock symbol for Intellia Therapeutics Inc is "38I."

What Is the Intellia Therapeutics Inc Market Cap?

As of today, Intellia Therapeutics Inc market cap is 868.43M.

What Is Intellia Therapeutics Inc's Earnings Per Share (TTM)?

The Intellia Therapeutics Inc EPS (TTM) is -5.21.

From a Technical Analysis Perspective, Is 38I a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Intellia Therapeutics Inc Stock Split?

Intellia Therapeutics Inc has split 0 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.